Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis
Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.
Intellia Becomes First To Show Potential For CRISPR Therapy Re-Dosing
The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.
Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
Cagrisema Leads The Charge For 2025
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead
Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.
First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor
AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.
Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say
The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.
Merck Investors Keeping A Close Watch On Winrevair Uptake
Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.